Startup profile · funding coverage
BigHat Biosciences
AI-guided antibody design platform (Milliner) for safer protein therapeutics.
Stage
series b
Status
private
Coverage
full
Why BigHat Biosciences is interesting
Tight ML–wet-lab loop compresses antibody optimization cycles — a16z-led A round with 8VC before Section 32-led scale-up.
Key facts
- Series A (Feb 2021): $19M led by a16z Bio + Health with 8VC participation (company press)
- Series B (Jul 2022): $75M led by Section 32; a16z and 8VC re-upped (BigHat Bio)
- Co-investors not in VCT directory: Section 32, AME Cloud Ventures, Amgen Ventures
- Source: https://www.bighatbio.com/news/bighat-biosciences-raises-19-million-in-series-a-funding-to-advance-antibody-design-and-development-for-safer-more-effective-treatments
Investors in our directory
Funds linked from BigHat Biosciences's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about BigHat Biosciences
Funding context and why this company shows up in venture coverage.
BigHat designs antibodies using its Milliner platform, which combines computational models with high-throughput lab experiments to shorten optimization cycles for biologic drug candidates.
Andreessen Horowitz (see /fund/andreessen-horowitz) led the Series A; 8VC (see /fund/8vc) participated. Section 32 led the $75M Series B in 2022 with a16z and 8VC re-upping.
Series B as of July 2022 ($75M). The company remains private and is developing antibody therapeutics with pharma partners.
It sits at the intersection of AI and wet-lab biologics — a tight ML–experiment loop that compresses antibody optimization timelines, a pattern other computational biology startups are copying.
No — BigHat remains a private biotech company headquartered in the San Francisco Bay Area.
Last updated: 2026-07-24